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Background: Abetalipoproteinemia (ABL; OMIM 200100) is a rare monogenic disorder of lipid metabolism
characterized by reduced plasma levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C) and
almost complete absence of apolipoprotein B (apoB). ABL results from genetic deficiency in microsomal triglyceride
transfer protein (MTP; OMIM 157147). In the present study we investigated two unrelated Tunisian patients, born
from consanguineous marriages, with severe deficiency of plasma low-density lipoprotein (LDL) and apo B.
Methods: Intestinal biopsies were performed and The MTTP gene was amplified by Polymerase chain reaction then
directly sequenced in patients presenting chronic diarrhea and retarded growth.
Results: First proband was homozygous for a novel nucleotide deletion (c. 2611delC) involving the exon 18 of
MTTP gene predicted to cause a non functional protein of 898 amino acids (p.H871I fsX29). Second proband was
homozygous for a nonsense mutation in exon 8 (c.923 G > A) predicted to cause a truncated protein of 307 amino
acids (p.W308X), previously reported in ABL patients.
Conclusions: We discovered a novel mutation in MTTP gene and we confirmed the diagnosis of
abetalipoproteinemia in new Tunisian families.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/8134027928652779.
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ABL is a rare autosomal recessive metabolic disorder
characterized by very low levels of total cholesterol (TC),
low density lipoprotein- cholesterol (LDL-C) and almost
the complete absence of apolipoprotein B-containing lipo-
proteins [1]. Patients with ABL have severe fat malabsorp-
tion, retarded growth, lipid accumulation in hepatocytes
and enterocytes, and peripheral blood acanthocytosis
essentially in early childhood, and later develop a retinitis
pigmentosa and neuropathy due to fat soluble vitamins
deficiency specifically vitamin E. Other manifestations of
ABL include also hepatic steatosis and hepatomegaly [2].* Correspondence: najahbs@yahoo.fr; Naceur. Slimene@fmm.rnu.tn
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reproduction in any medium, provided the orHeterozygotes ABL patients usually have normal plasma
levels of TC and LDL-C [3].
ABL is due to mutations in the MTTP gene encoding
for the microsomal triglyceride transfer protein (MTP) a
protein of 97-kDa, containing 894 amino acids, that
forms an heterodimer with the protein disulfide isomerase
(PDI). MTP protein is essentially expressed in endoplasmic
reticulum of hepatocytes and enterocytes and plays a key
role on the assembly and secretion of apo B-containing
lipoproteins in both liver and intestine [4-7].
The MTP molecule consists of three structural domains:
N-terminal β-barrel (residues 22–297), α-helical (residues
298–603) and C-terminal domains (residues 604–894).
The N-terminal β-barrel domain mediates the interaction
with the N terminus of apo B; the middle α-helical domain
mediates the interaction with both PDI and apo B; and thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activity of MTP [6,8,9].
To our knowledge, more than 50 patients with ABL
were described in the literature. Most of MTTP gene
mutations result in truncated proteins [10,11]. Missense
mutations have been also reported in atypical cases of
ABL and were associated with a milder form of the
disease [12-14].
The aim of the present study was to characterize two
unrelated Tunisian patients with the clinical manifestations
and plasma lipid profile consistant with ABL. They were
found to be homozygous for two mutations respectively,
one of which is new inMTTP gene.
Methods
Clinical data and recruitment of family members
All subjects investigated are living in Tunisia and are
of Tunisian ancestry. Informed consent was obtained
from all adult subjects, and in the case of children,
from their parents. The study was approved by the Ethics
Committees of each participating institution. Family
members (parents and their child) of the patients were
asked to take part in the study.
Patient II.1 (Family E)
The proband (subject II.1 in Figure 1) is a one year-old
girl, born from a consanguineous marriage. She was
referred to the hospital at the age of 10 months for the
presence of hypotrophy and retarded growth. First
observation showed that patient presented a steatorrhea
(11.54 g/24 hours) with episodes of diarrhea. On physical
examination, her weight was 3700 g and she had a height
standard deviation score of −4.8 SDS.
Exploration showed that levels of ASAT and ALAT
were 169 IU/L (normal values <38 IU/L) and 214 IU/L
(normal values <41 IU/L) respectively. A normal level
of gammaglutaryl transferase: 16 IU/L and an elevationFigure 1 Pedigree of Family E. The proband is indicated by the
arrow. Subject homozygote for the MTP gene mutation (c.2611delC) is
indicated by close symbol, heterozygous carriers are indicated by
half-shaded symbols.of alcaline phosphatase (179 IU/L) (normal values 40–
150 IU/L) were observed. Calcemia and total protein
were normal. Acanthocytosis was revealed on peripheral
blood smear. The lipid levels at the time of hospitalization
were CT: 1.3 mmol/l, TG: 0.35 mmol/l and HDL-C: 0.9 -
mmol/l. Values of vitamins were 430 μg/l for vitamine A
(normal values 444–945 μg/l), vitamine E (<1 μmol/l) was
undetectable (normal values 16–35 μmol/l). The patient
was treated by restricting dietary fat and by supplementa-
tion of fat soluble vitamin A 25 000 IU daily and vitamin
E 500 mg daily during three months. No neurological or
ophthalmic abnormalities were found.
Patient II.2 (Family D)
The proband (subject II.2 in Figure 2) is a 20 year–old
boy born from a consanguineous marriage. He suffered
from a long history of sever hypobetalipoproteinemia.
Clinical data showed that he was first referred to the
hospital at the age of 5 months for the exploration of a
prolonged diarrhea and retarded growth. Followed by
oral and venous rehydration, antibiotherapy and a diet
excluding proteins of cow’s milk; the evolution of the
child was fluctuating. He left the hospital without any
retained diagnosis; a low -fat diet was prescribed. The
patient was present for a second examination at 4 years
of age with chronic diarrhea and postprandial vomiting
and retarded growth (−3DS). At this time a difficulty of
the vision (twilight and night) and a disorder of walking
were first observed. Anemia (Hb 8.9 mg/dl) and vitamine E
deficiency (Vit E < 1 μmol/l) (normal values 16–35 μmol/l)
were noted. Acanthocytosis was revealed on peripheral
blood smear. At this age the diagnosis of familial
hypobetalipoproteinemia was taken upon the low plasmatic
lipids levels (CT: 1.28 mmol/l; TG: 0.31 mmol/l; apoB and
LDL-C: undetectable). Ophthalmic examinations showed a
peripheral hyperpigmentation of the retina. Neurological
examinations revealed the presence of cerebellar syndromeFigure 2 Pedigree of Family D. The proband is indicated by the
arrow. Subject homozygote for the MTP gene mutation (c.923 G > A) is
indicated by close symbol; heterozygous carriers are indicated by
half-shaded symbols. Family member not available for the study is
indicated by an asterisk.
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was treated, during one year, by oral vitamin A 25 000 IU
daily, vitamin E 800 mg daily, and vitamin K 40 mg every
15 days, the postprandial vomiting, walk and osteo-
tendinous reflexes were normalized with a growth amelior-
ation (−1DS). The other observations were not changed
except the normalization of hemoglobin. Then, 5 mg daily
of vitamin K were changed in his treatment and he was
followed yearly until the age of 12 years. His health
remained stable (Lipid values during follow-up were not
documented in the clinical database). At age 20, he was
hospitalized again, Neurological and ophthalmic exami-
nations revealed a complete absence of osteo-tendinous
reflexes, sensitive axonal neuropathy and pigmentary
retinal degeneration. The hepatic ultrasound examination
showed the presence of fatty liver. Plasma triglycerides
and cholesterol were decreased, with undetectable
LDL-C, ApoB and Vitamin E (Vit E <1 μmol/l). As the
treatment was stopped for a long period the initial
doses of vitamins were prescribed associated with a
restricting dietary fat.
Lipid and lipoprotein analysis
For all family members plasma lipid values were obtained
after an overnight fast. Plasma TC, TG and HDL-C
concentrations were measured by a standard method using
the Synchrom CX7 clinical system (Beckman, Fullerton,
CA, USA). LDL-C concentration was calculated using the
Friedewald’s Formula. ApoA-I, apoB were measured by
immunonephelometry using the IMMAGE immunochem-
istry system (Beckman, Fullerton, CA, USA).
Intestinal biopsy
Following a period of 12 hours fasting, duodenal biopsies
were obtained from probands. Tissues were fixed in 10%
buffered formalin and embedded in paraffin for routine
histology stained with hematoxylin and eosin.
Molecular analysis
Genomic DNA was isolated from whole blood EDTA
samples using the salting-out method [15]. For the
family E patient, MTTP gene was amplified and directly se-
quenced as previously described [16]. In the case of family
D, The promoter and all exons as well as flanking intronic
sequences of theMTTP gene were amplified by polymerase
chain reaction (PCR) as previously described [10], then
PCR products were sequenced using BigDyeDeoxy
terminator cycle sequencing reagents according to the
manufacturer’s instructions and templates were sequenced
on an automated ABI-PRISM 310 Genetic Analyzer
(Applied Biosystems). Further, theMTTPmutations found
in the probands were screened by direct sequencing in all
family members available for study.Mutation nomenclature
MTTP mutations were designated according to the Human
Genome Variation Society. Nucleotide numbers are derived
from MTTP cDNA sequence (GenBank accession no.
NM_000253.2), considering the A of first ATG translation
initiation codon as nucleotide +1. Amino acid sequence
MTP protein are described according to the National
Center for Biotechnology Information reference sequence
(MTP, GenBank accession no. NP_000244.2).
Results
The first proband of family E (subject II.1 in Figure 1 and
Table 1) had extremely low plasma lipids with undetectable
LDL-C and apoB (Table 1). As no data are available for the
Tunisian population [10-34], the lipid values were
compared to the 95th percentile of the levels found in
the European populations suggesting a condition of
hypobetalipoproteinemia [3]. The duodenal biopsy showed
the presence of enterocyte vacuolization specifically at the
tip of the villi suggestive of fat accumulation (Figure 3).
Proband’s parents (Table 1) had a normal plasma lipid
profile, strongly suggesting that the child might have
ABL. The analysis of MTTP gene revealed that the pro-
band was homozygous for a novel deletion in the exon
18 (c. 2611delC) expected to cause a frameshift in the
mRNA by changing the sequence of the 23 last amino
acids on C-terminal domain (residues 604–894) and
adding 3 amino acids. The translation product of this
abnormal mRNA is an MTP protein containing 898
amino acids (p.H871I fsX29) instead of 894 amino
acids of the normal protein (Additional file 1). Proband’s
parents were heterozygous.
The second proband of family D (subject II.2, in
Figure 2 and Table 2) had extremely low plasma
lipids. Plasma LDL-C and apoB were undetectable.
The duodenal biopsy showed the presence of enterocyte
vacuolization suggesting the presence of lipid droplets
(Figure 4). Proband’s father (subject I.2 in Table 2) had a
normal plasma lipid profile. Although the proband’s
mother (subject I.1 in Table 2) had plasma levels of TC,
LDL-C and apoB below the 95th percentile of the levels
found in the European populations it was not possible to
define to what extent the values observed in proband’s
mother diverge from the mean in our population. The
proband’s brother (subject II.1 in Table 2) had also low
plasma lipids.
In view of the lipid profile of proband’s parents and
because we already described a Tunisian ABL family
whith hypocholesteroleima in one of his parents [10], we
assumed that the proband might be affected by ABL.
The sequence of MTTP gene showed that the proband
was homozygous for (c.923 G > A) mutation in exon 8.
The result is a truncated protein of 307 amino acids, as
opposed to the 894 amino acids, devoid of function.
Table 1 Plasma lipid and apolipoprotein levels in Family E
Subject Age (years) TC TG LDL-C HDL-C ApoB ApoA-I
Mmol/l mg/dl
I.1 33 4.39 1.47 2.6 1.16 70 178
I.2 38 5.46 1.09 3.08 1.63 87 191
II.1 1 0.58 0.14 und 0.37 und 49
Normal range 3.9-6.7 0.68-1.7 2.5-4.4 >1.2 30-95 90-200
TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; Apo, apolipoprotein; und,
undetectable.
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(subject II.1 in Figure 2) present on this study was normal.
Discussion
ABL is a rare autosomal recessive metabolic disorder char-
acterized by complete absence of plasma apo B-containing
lipoproteins that results from mutations in MTTP gene.
Patients with ABL may develop severe neurological
manifestations if they are not treated [2,17,18].
Abetalipoproteinemia is characterized, in term of
clinical manifestations, with homozygous Familial
Hypobetalipoproteinmia (FHBL; OMIM 107730) and
Chylomicron Retention disease (CMRD; OMIM 246700),
two other monogenic disorders of lipid metabolism by
manifestations such as steatorrhea, retarded growth and
chronic diarrhea associated with hypocholesterolemia.
Under these conditions the use of the lipid profile of
proband’s parents is essential to lead and facilitate the
molecular diagnosis of these metabolic disorders: familial
hypobetalipoproteinemia is a rare autosomal codominant
disorder of lipoprotein metabolism, it results that bothFigure 3 Light microscopy of the duodenal biopsy from the ABL
patient of family E showed clusters of vacuolated enterocytes
specifically at the tip of the villi (indicated by the arrow)
(× 200 magnification).parents are expected to have plasma levels of TC, LDL-C
and apoB lower than those found in normal subjects
[3,19]. In ABL and CMRD with an autosomal recessive
transmission, obligate heterozygotes have almost normal
plasma lipoprotein profiles, with some exception and
usually normal level of TG in patients homozygous for
CMRD [2,20].
In this paper, we characterize two new Tunisian
families with a severe form of hypobetalipoproteinemia.
The common clinical features shared by patients were
diarrhea, failure to thrive, acanthocytosis and lipid
accumulation in enterocytes. The diagnosis of ABL was
confirmed in these families and patients were found to
be homozygotes for two mutations; one of them, which
involves the exon 18, is novel on MTTP gene.
In the case of families E and D, probands presented
with a similar lipid profile and very low plasma levels of
TC, TG and undetectable LDL-C and apoB. In family E,
the lipid values of proband’s parents, were within the
normal range (Table. 1). The MTTP gene sequencing
showed that proband of family E was homozygous for a
novel mutation on MTTP gene (c.2611delC), predicted
to result in a protein of 898 amino acids. It is well
known that C-terminal domain (residues 604–894) me-
diate the lipid binding and the transfer catalytic activity
of MTP [8,27]. The abnormal protein is expected to be
non functional, since the sequence of the C-terminal do-
main was changed. It was demonstrated that C-terminal
domain is preferentially conserved amongst vertebrates
suggesting that this region might be critical for the
triacylglycerol transfer activity associated with MTP [28].
The truncated MTP protein resulting from the mutation
(p.G865X), involving the exon 18, was suggested to
interfere with the association between the 97 kD subunit
of MTP and PDI [24,29]. Other MTP truncations devoid
of the C-terminal domain [25,30] or missense mutations
located in this domain [12,13] have been described in
patients with ABL highlighting the functional role of the
C-terminal domain.
In family D, we found the third Tunisian patient with
(c.923 G > A) mutation in homozygous state. This muta-
tion was found for the first time in two Tunisian affected
brothers (unrelated to the patient in the present study)
Table 2 Plasma lipid and apolipoprotein levels in Family D
Subject Age (years) TC TG LDL-C HDL-C ApoB ApoA-I
Mmol/l mg/dl
I.1 55 2.9 0.7 1.4 1.2 68 149
I.2 75 4.1 0.87 2.11 1.59 94 135
II.1 15 2.3 0.79 0.59 1.42 35 100
II.2 20 1.3 0.35 Und 0.9 und 35
Normal range 3.9-6.7 0.68-1.7 2.5-4.4 >1.2 30-95 90-200
TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; Apo, apolipoprotein; und,
undetectable.
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acids (p.W308X) devoid of function [10]. The proband’s
parents were heterozygous and his brother was normal.
Proband’s mother (subject I.1 in Table 2) had low plasma
lipid levels suggestive of hypobetalipoproteinemia, even
though, the lipid plasma values within the lower limit or
low values of TC and apoB were observed in heterozygous
subjects for the same mutation (c.923 G > A) in a previous
study [10]. This is not surprising as heterozygous ABL
(specifically one of the parents) were reported with low
plasma TC, LDL-C and apoB in other single families
[21-23], and the possibility that human MTP deficiency
is inherited in a codominant manner had been also
suggested in heterozygous of MTP knockout mice with
reduced plasma apoB levels [35].
The proband’s brother (subject II.1 in Table 2), with
normal genotype, had low levels of TC and apoB
although he was healthy and had no history of malab-
sorption or failure to thrive. The biochimical phenotype
of family D strongly confirms the existence of a Tunisian
specificity associated with monogenic dyslipidemias,
since we recently showed a low level of plasma lipids in
heterozygous for CMRD [36] and normal or moderate
levels of CT and LDL-C in heterozygous familial
hypercholestetolemia (FH) [37]. The lipid profile of pro-
band’s brother (subject II.1 in Table 2) can be attributedFigure 4 Light microscopy of the duodenal biopsy from the ABL pati
specifically at the tip of the villi (indicated by the arrow) (× 200 magneither to the low content of fats in the mediterranean
diet which characterize Tunisian population [38] or to
the coexistence of other cholesterol-lowering gene(s)
associated with hypobetalipoproteinemia in this family.
In addition, it has been shown that some polymorphisms
in genes related to the metabolism of lipoproteins, have
been associated with lipid levels in Tunisian patients
affected by other diseases like cardiovascular pathologies
[39]. This reflects, in part, the genetic background
heterogeneity of the Tunisian population demonstrated
in other genetic disorders [40].
Many mutations in MTTP gene described in literature
as cause of ABL were private and related to single
families. There was an exception with (p.G865X) muta-
tion which was found in ABL patients from USA and
Canada and was also reported in the Ashkenazi Jewish
population with a high prevalence and a founder effect
[12,25]. The (419insA) mutation was also associated
with ABL in patients of European ancestry [13,26]. In
Tunisian population, four mutations in MTTP gene
(c.923 G > A, c.619-3 T > G, c.1236 + 2 T > G and
c.2342 + 1 G > A) have been reported as cause of ABL
in four single families [10,36]. In this study, the diagno-
sis of the mutation (c.923 G > A) in a new Tunisian
family is suggestive of a high prevalence of the mutant
allele in heterozygote state.ent of family D showed clusters of vacuolated enterocytes
ification).
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complete (especially hepatic exploration), our patients
presented the typical hematologic and gastrointestinal
features of ABL such as acanthocytosis, diarrhea
during infancy and malabsorption with mild anemia
(proband II.2 of family D in this paper) which was reported
in some cases of ABL [10,21]. Usually neurological
manifestations begin later in life in ABL patients, especially
those who have not been given a supplementation of
vitamin E [31]. Later supplementation of fat soluble vi-
tamins in patient II.2 (family D) allowed the osteotendinous
reflexes reduction. Previous studies showed that early ther-
apy with vitamin E, before the age of 16 months prevents
neurologic dysfunction [32,33]. Elevated Transaminases
serum of the proband II.1 (family E) is suggestive of hepatic
steatosis which is needed to be confirmed by liver biopsy in
this patient. It was reported that hepatic manifestations in
ABL cases included hepatomegaly due to hepatic steatosis
in association with elevated transaminases [34,41]. The
absence of neurological and opthalmological manifestations
in patient II.1 (family E) is consistant with the observation
that the diagnosis of ABL should be made in children with
malabsorption, acanthocytosis and hypocholesterolemia.
Indeed a low-fat diet and fat-soluble vitamins supple-
mentation can prevent later complications [17].Conclusion
Five ABL patients have been reported in Tunisian popu-
lation [10,36]. In this work we characterize two other
unrelated patients affected by this metabolic disorder
and we identify a novel mutation in MTTP gene leading
to a non functional protein. Although it is a rare disease,
abetalipoproteinemia seems to have a high prevalence in
Tunisia. Knowledge of MTTP gene mutations allows us
to set up a sensitive and specific use of genetic testing
for screening carriers in other families.Additional file
Additional file 1: Analysis of the MTTP gene. The chromatogram
show the partial sequence of exon 18 in the proband II.1 (family E). In
above, the normal MTTP gene sequence (reference NM_000253). In the
below, mutant sequence show the homozygous state of the novel
nucleotide deletion (c. 2611delC) and the frameshift in the mRNA. The
predicted translation product of the mutant MTTP gene is a non
functional protein of 898 amino acids (p.H871I fsX29) lacking the last 23
functional amino-acids.Abbreviations
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